TAX-326

Regimen

Experimental
docetaxel+cisplatin or docetaxel+carboplatin
Control
vinorelbine+cisplatin

Population

Stage IIIB/IV chemo-naive NSCLC

Key finding

DC vs VC: mOS 11.3 vs 10.1 mo, HR 1.183 (95% CI not explicitly in abstract); established docetaxel doublet as alternative 1L standard

Source: PMID 12837811

Timeline

    Guideline citations

    • NCCN NSCLC Version 5.2026 (p.94)